These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 19886836

  • 41. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V.
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [Abstract] [Full Text] [Related]

  • 42. [Current role of tenofovir in clinical medicine].
    Ribera Pascuet E, Curran A.
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():45-54. PubMed ID: 19338072
    [Abstract] [Full Text] [Related]

  • 43. [Tenofovir DF in rescue regimens].
    López Bernaldo de Quirós JC.
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
    [Abstract] [Full Text] [Related]

  • 44. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL.
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [Abstract] [Full Text] [Related]

  • 45. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM, Mayer KH.
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [Abstract] [Full Text] [Related]

  • 46. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
    Miller MD, Haddad M, Su C, Gibbs C, McColl DJ, Guyer B.
    Antivir Ther; 2012 Feb; 17(6):993-9. PubMed ID: 22837442
    [Abstract] [Full Text] [Related]

  • 47. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB.
    AIDS; 2001 Oct 19; 15(15):1951-7. PubMed ID: 11600822
    [Abstract] [Full Text] [Related]

  • 48. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.
    HIV Clin Trials; 2011 Oct 19; 12(5):255-67. PubMed ID: 22180523
    [Abstract] [Full Text] [Related]

  • 49. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, Frenkel L, Britto P, Roongpisuthipong A, Beck IA, Yuthavisuthi P, Prommas S, Puthanakit T, Achalapong J, Chotivanich N, Rasri W, Cressey TR, Maupin R, Mirochnick M, Jourdain G, IMPAACT P1032 Protocol Team.
    Clin Infect Dis; 2012 Jan 15; 54(2):285-93. PubMed ID: 22144539
    [Abstract] [Full Text] [Related]

  • 50. Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine.
    Amoroso A, Gilliam BL, Talwani R, Boyce C, Redfield RR, Davis CE.
    HIV Clin Trials; 2009 Jan 15; 10(5):320-3. PubMed ID: 19906624
    [Abstract] [Full Text] [Related]

  • 51. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM, Partners PrEP Study Team.
    JAMA; 2009 Jan 15; 312(4):362-71. PubMed ID: 25038355
    [Abstract] [Full Text] [Related]

  • 52. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
    Dolling D, Phillips AN, Delpech V, Pillay D, Cane PA, Crook AM, Shepherd J, Fearnhill E, Hill T, Dunn D, UK HIV Drug Resistance Database, UK Collaborative HIV Cohort (UK CHIC) Study.
    HIV Med; 2012 May 15; 13(5):309-14. PubMed ID: 22151684
    [Abstract] [Full Text] [Related]

  • 53. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
    Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L, ARTEN investigators.
    Antivir Ther; 2011 May 15; 16(3):339-48. PubMed ID: 21555816
    [Abstract] [Full Text] [Related]

  • 54. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
    McMahon DK, Zheng L, Hitti J, Chan ES, Halvas EK, Hong F, Kabanda J, Taulo F, Kumarasamy N, Bonhomme J, Wallis CL, Klingman KL, Hughes MD, Mellors JW.
    Clin Infect Dis; 2013 Apr 15; 56(7):1044-51. PubMed ID: 23300238
    [Abstract] [Full Text] [Related]

  • 55. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
    Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R, Carrou JL, Bohoussou F, Eholie SP, Anglaret X.
    J Int AIDS Soc; 2013 Apr 30; 16(1):18059. PubMed ID: 23639243
    [Abstract] [Full Text] [Related]

  • 56. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
    Persaud D, Bedri A, Ziemniak C, Moorthy A, Gudetta B, Abashawl A, Mengistu Y, Omer SB, Isehak A, Kumbi S, Adamu R, Lulseged S, Ashworth R, Hassen E, Ruff A, Ethiopian Swen Study Team.
    AIDS Res Hum Retroviruses; 2011 Aug 30; 27(8):823-9. PubMed ID: 21241214
    [Abstract] [Full Text] [Related]

  • 57. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
    Jones D, Parkin N, Hudelson SE, Guay LA, Musoke P, Mmiro F, Jackson JB, Eshleman SH.
    AIDS Res Hum Retroviruses; 2005 Apr 30; 21(4):319-24. PubMed ID: 15943576
    [Abstract] [Full Text] [Related]

  • 58. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    Toni TD, Masquelier B, Lazaro E, Dore-Mbami M, Ba-Gomis FO, Téa-Diop Y, Kouakou K, Diby J, Sia E, Soppi S, Essien S, Schrive MH, Pinson P, Chenal H, Fleury HJ.
    AIDS Res Hum Retroviruses; 2005 Dec 30; 21(12):1031-4. PubMed ID: 16379606
    [Abstract] [Full Text] [Related]

  • 59. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M, Ordoñez-Llanos J, Martínez E, Barragán P, Ribera E, Bonet R, Knobel H, Negredo E, Loncá M, Curran A, Gatell JM, Podzamczer D, Bicombo-met Substudy Team.
    Antivir Ther; 2011 Dec 30; 16(4):459-68. PubMed ID: 21685533
    [Abstract] [Full Text] [Related]

  • 60. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
    Uglietti A, Zanaboni D, Gnarini M, Maserati R.
    Expert Opin Drug Metab Toxicol; 2012 Oct 30; 8(10):1305-14. PubMed ID: 22943210
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.